Scholarlink

<p>Gross hematuria (GH) following COVID-19 mRNA vaccination has been increasingly reported in patients with IgA nephropathy (IgAN). This study assessed the effect of post-vaccination GH on kidney function. A total of 441 Japanese outpatients with biopsy-confirmed IgAN (median age: 51 years; 56% female; baseline eGFR: 57 mL/min/1.73&#xa0;m²) were classified into three groups: unvaccinated (<i>n</i> = 25), vaccinated without GH (<i>n</i> = 391), and vaccinated with GH (<i>n</i> = 25). Kidney function was evaluated at approximately 1 year (midpoint) and 2 years (endpoint) after baseline. The annual eGFR change (ΔeGFR: mL/min/1.73&#xa0;m²/year) at midpoint was − 1.16, − 1.03, and − 2.50, respectively. The GH group showed a significantly greater decline compared to the non-GH group (<i>p</i> = 0.015), and GH was significantly associated with greater eGFR decline at midpoint (odds ratio: 2.97, <i>p</i> = 0.038). At the endpoint, the ΔeGFR was − 0.45, − 1.93, and − 1.72, with no significant differences among the groups (<i>p</i> = 0.773). In this cohort, GH after vaccination was observed to be associated with a greater short-term decline in kidney function, although the retrospective design precludes establishing causality.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Gross hematuria after COVID-19 mRNA vaccination and kidney function trajectory in IgA nephropathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月8日

查看全文
  • Shinya Yokote,
  • Masahiro Okabe,
  • Akihiro Shimizu,
  • Kotaro Haruhara,
  • Shohei Fukunaga,
  • Takaya Sasaki,
  • Toshinari Fujimoto,
  • Hiroyuki Ueda,
  • Nobuo Tsuboi,
  • Takashi Yokoo

摘要

Gross hematuria (GH) following COVID-19 mRNA vaccination has been increasingly reported in patients with IgA nephropathy (IgAN). This study assessed the effect of post-vaccination GH on kidney function. A total of 441 Japanese outpatients with biopsy-confirmed IgAN (median age: 51 years; 56% female; baseline eGFR: 57 mL/min/1.73 m²) were classified into three groups: unvaccinated (n = 25), vaccinated without GH (n = 391), and vaccinated with GH (n = 25). Kidney function was evaluated at approximately 1 year (midpoint) and 2 years (endpoint) after baseline. The annual eGFR change (ΔeGFR: mL/min/1.73 m²/year) at midpoint was − 1.16, − 1.03, and − 2.50, respectively. The GH group showed a significantly greater decline compared to the non-GH group (p = 0.015), and GH was significantly associated with greater eGFR decline at midpoint (odds ratio: 2.97, p = 0.038). At the endpoint, the ΔeGFR was − 0.45, − 1.93, and − 1.72, with no significant differences among the groups (p = 0.773). In this cohort, GH after vaccination was observed to be associated with a greater short-term decline in kidney function, although the retrospective design precludes establishing causality.